Clinical trials: HIV Risk Reduction
HIV Infections
Reducing HIV Risks in African American Teens
This study is developing and testing an innovative, parent education intervention, Preparing Our Sons and Daughters for Healthy Futures.
- Trial name
- NCT00963963
- Testing
- Healthy Futures parent education
- Where
- United States
- Volunteers
- 1,200 people
- Sponsor
- Education Development Center, Inc.
HIV Infections, Dyslipidemias
Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)
This is a phase 2, randomized, double-blinded, placebo-controlled clinical trial. The intervention drug will be efprezimod alfa (intravenous [IV] infusion).
- Trial name
- CALIBER (NCT03960541)
- Testing
- Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)